YGR283C Antibody

What is YGR283C and what are its basic specifications?

YGR283C is a polyclonal antibody raised in rabbits against recombinant Saccharomyces cerevisiae YGR283C protein. The antibody is specifically designed to recognize the YGR283C protein (UniProt No. P53336) from S. cerevisiae strain ATCC 204508/S288c (Baker's yeast). It is supplied in liquid form in a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative. This antibody has been purified using antigen affinity methods to ensure high specificity .

What experimental applications has YGR283C antibody been validated for?

The YGR283C antibody has been validated for specific research applications including:

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Western Blotting (WB)

These applications have been tested to ensure proper identification of the target antigen. It is important to note that this antibody is intended for research use only and not for diagnostic or therapeutic procedures .

How should YGR283C antibody be stored to maintain optimal activity?

Proper storage is critical for maintaining antibody functionality. Upon receipt, YGR283C antibody should be stored at either -20°C or -80°C. Repeated freeze-thaw cycles should be strictly avoided as they can lead to protein denaturation and loss of antibody activity. The antibody is supplied in a buffer containing 50% glycerol, which helps prevent freezing damage and maintains stability during storage .

What controls should be included when designing experiments with YGR283C antibody?

When designing experiments using YGR283C antibody, several controls are essential for result validation:

• Positive control: Include samples known to express YGR283C protein from S. cerevisiae strain ATCC 204508/S288c.

• Negative control: Use samples from organisms that do not express the target protein or knockout (KO) cell lines lacking the target gene, similar to approaches used in antibody characterization platforms like YCharOS .

• Isotype control: Include a rabbit IgG isotype control at the same concentration as the primary antibody to identify potential non-specific binding.

• Secondary antibody control: Perform a control without primary antibody to assess background from the detection system.

• Cross-reactivity control: Include samples from related yeast strains to evaluate potential cross-reactivity with similar proteins.

How can immunoprecipitation protocols with YGR283C antibody be optimized?

Based on immunoprecipitation methodologies for similar antibodies, the following optimization strategies are recommended:

• Pre-clearing lysates: Pre-clear cellular lysates with protein A/G beads before adding the antibody to reduce non-specific binding, similar to the approach used for CU-28-24 antibody .

• Antibody immobilization: Immobilize YGR283C antibody on protein A/G columns by running the purified antibody over the column multiple times to ensure maximal binding .

• Sample application: Apply your target protein sample to the column multiple times (at least 3×) to maximize antigen capture .

• Washing optimization: Perform extensive washing with PBS (at least 4 wash cycles) to remove non-specifically bound proteins .

• Elution conditions: Elute bound proteins using 0.05M glycine at pH 2.5, collecting in tubes containing neutralizing buffer (such as carbonate buffer, pH 9) to prevent protein denaturation .

• Verification: Verify successful immunoprecipitation through subsequent analysis by SDS-PAGE and immunoblotting .

What are the key considerations for Western blot experiments using YGR283C antibody?

When performing Western blot experiments with YGR283C antibody, consider these technical aspects:

How can I validate the specificity of YGR283C antibody in my experiments?

Multiple complementary approaches can be used to validate antibody specificity:

• Knockout validation: The gold standard for antibody validation involves using knockout cells lacking the target gene. Signal absence in knockout samples confirms specificity .

• Multi-application testing: Validate the antibody across different applications (ELISA, WB, etc.) to ensure consistent target recognition .

• Epitope mapping: Determine the specific epitope recognized by the antibody through peptide walking or competition assays with synthetic peptides .

• Side-by-side comparison: Compare multiple antibodies against the same target in standardized experiments, as practiced by initiatives like YCharOS .

• Sequence-based analysis: Confirm antibody specificity against closely related proteins through bioinformatic analysis and experimental validation .

What methods are available for characterizing antibody binding modes and epitopes?

Advanced methodologies for characterizing antibody binding include:

• Biophysics-informed modeling: Computational models can be trained on experimental data to identify distinct binding modes associated with different ligands. This approach uses shallow dense neural networks to parametrize binding energies .

• Phage display experiments: These can reveal specific binding profiles by selecting antibodies against various combinations of ligands. This approach allows for training and testing of computational models .

• Peptide walking: Generate overlapping synthetic peptides to screen the antibody by ELISA, identifying specific binding regions. The peptide recognized by ELISA should also block antibody binding to the whole protein .

• Competitive binding assays: Use defined peptides or ligands in competition assays to determine if they block antibody binding to the target protein .

• Structural analysis: When possible, X-ray crystallography or cryo-EM can provide detailed information about antibody-antigen binding interfaces.

How do standardized antibody characterization platforms improve experimental reproducibility?

Standardized antibody characterization platforms significantly enhance reproducibility through:

• Consistent methodology: Platforms like YCharOS implement standardized protocols for antibody testing across key applications (immunoblotting, immunoprecipitation, immunofluorescence) .

• Knockout validation: Systematic use of knockout cell lines provides definitive specificity validation .

• Cross-manufacturer comparison: Side-by-side testing of antibodies from different manufacturers under identical conditions allows direct performance comparison .

• Open data sharing: Public availability of characterization data enables researchers to make informed decisions about antibody selection .

• Industry collaboration: Collaborations between academic institutions and antibody manufacturers (as seen with YCharOS, involving 11 major manufacturers) help establish industry-wide standards .

What are common causes of false positive results when using antibodies like YGR283C?

False positive results may arise from several sources:

• Insufficient specificity: Many commercially available antibodies lack adequate specificity, leading to off-target effects and an estimated $1 billion of research funding wasted annually .

• Epitope destruction: Some antibodies (like CU-28-24) may not recognize their targets under denaturing conditions, potentially causing discrepancies between different assay formats .

• Cross-reactivity: Antibodies may recognize similar epitopes in related proteins, especially when targeting conserved domains.

• Protocol variations: Inconsistent experimental conditions across labs can lead to variable results even with the same antibody.

• Batch-to-batch variability: Different production batches may show varying performance characteristics, particularly for polyclonal antibodies.

To mitigate these issues, comprehensive validation across multiple applications and careful optimization of experimental conditions are essential.

How can computational models improve antibody specificity design?

Computational approaches offer powerful tools for designing antibodies with custom specificity profiles:

• Biophysics-informed modeling: Models trained on phage display data can disentangle multiple binding modes associated with specific ligands, enabling the prediction and generation of specific variants beyond those observed experimentally .

• Custom specificity profiles: Computational models can be used to design antibodies with either:

  • Specific high affinity for a particular target ligand

  • Cross-specificity for multiple target ligands

• Energy function optimization: By optimizing energy functions associated with different binding modes, researchers can generate novel antibody sequences with predefined binding profiles:

  • For cross-specific sequences: Jointly minimize energy functions for desired ligands

  • For specific sequences: Minimize energy for desired ligand while maximizing energy for undesired ligands

• Experimental validation: Computational predictions should be validated experimentally, as demonstrated in studies that successfully designed antibodies with customized specificity profiles .

How do epitope characteristics affect antibody performance across different applications?

Epitope characteristics significantly impact antibody functionality:

• Conformational vs. linear epitopes: Antibodies recognizing conformational epitopes (like potentially YGR283C) may perform well in applications maintaining native protein structure (ELISA, IP) but poorly in denaturing conditions (SDS-PAGE/immunoblotting) .

• Epitope accessibility: In some cases, epitopes predicted to be highly immunogenic may not be accessible in the native full protein structure, affecting antibody binding efficiency .

• Peptide design considerations: When designing peptides for antibody generation:

  • Peptide solubility affects immunization efficiency

  • N-terminal amino acids can influence peptide conformation

  • Multiple internal glycines can hamper conformational structure

• Native protein recognition: Some antibodies may recognize synthetic peptides well but bind poorly to the native protein, as seen with antibody CU-P1-1 which recognized its peptide but did not bind well to the full protein in ELISAs .

What standards should be applied when reporting YGR283C antibody experimental data?

Rigorous reporting standards enhance reproducibility:

• Complete antibody information: Include catalog number, lot number, manufacturer, host species, clonality, and immunogen details .

• Validation data: Provide evidence of antibody specificity through knockout controls or other validation methods .

• Experimental conditions: Document detailed protocols including antibody dilutions, incubation times/temperatures, and buffer compositions.

• Positive and negative controls: Always include and report appropriate controls used to validate experimental results.

• Quantification methods: Describe image acquisition parameters, quantification software, and statistical methods used for data analysis.

How is the Open Science movement addressing antibody reproducibility challenges?

The Open Science approach is transforming antibody research through:

• Standardized characterization: Initiatives like YCharOS (Antibody Characterization through Open Science) have developed standardized platforms to evaluate antibody specificity .

• Industry collaboration: Unprecedented collaborations among competing antibody manufacturers (11 major companies representing approximately 80% of global renewable antibody production) are enabling standardized antibody testing .

• Economic impact: By addressing the estimated $1 billion wasted annually on non-specific antibodies, these initiatives are improving research efficiency .

• Data sharing: Open access to antibody characterization data helps researchers make informed decisions when selecting antibodies for their research .

• Methodology standardization: The publication of standardized protocols enables researchers to adopt consistent characterization methods across laboratories .